Skip to main content

Table 2 Routine laboratory tests, vital signs, and body mass index before, during, and after roxadustat treatment

From: Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis

 

2019

2020

May

Jun.

Jul.

Aug.

Sept.

Oct.

Nov.

Dec.

Jan.

Feb.

Mar.

Apr.

May

Jun.

Jul.

Aug.

Sept.

Treatment for anemia

DARBE

DARBE

DARBE

DARBE

DARBE

DARBE

DARBE

DARBE

DARBE

ROXAD

ROXAD

ROXAD

ROXAD

DARBE

DARBE

DARBE

DARBE

Hemoglobin (g/dL)

9.4

9.5

9.8

10.6

9.5

8.3

9.3

9.2

9.0

8.5

8.9

9.2

8.8

7.9

8.2

7.2

7.5

TC (mg/dL)

126

124

115

113

120

110

123

129

127

76

67

64

52

67

122

111

126

Non-HDL-C (mg/dL)

88

—

85

—

87

—

91

—

92

—

49

47

33

43

85

80

92

HDL-C (mg/dL)

30

—

30

—

33

—

32

—

36

—

18

17

19

24

37

31

34

AST (IU/L)

18

17

16

18

17

17

22

19

7

18

19

20

17

19

18

17

17

ALT (IU/L)

8

8

8

8

8

8

9

8

8

9

8

10

9

9

7

7

7

Serum albumin (g/dL)

3.6

3.5

3.3

3.4

3.4

3.3

3.5

3.5

3.4

3.0

3.1

3.4

3.4

3.2

3.5

3.2

3.4

BUN (mg/dL)

36.3

54.3

52.2

58.0

47.8

61.2

55.5

60.5

48.6

57.4

48.3

51.6

50.9

40.8

39.4

43.8

54.2

Creatinine (mg/dL)

8.9

8.9

9.7

9.8

9.6

9.7

9.6

9.2

9.5

8.2

8.1

7.6

7.2

6.5

7.0

8.0

8.9

CRP (mg/dL)

0.27

0.68

0.22

0.13

0.37

0.38

0.28

0.19

0.24

0.43

0.30

0.25

0.23

0.28

0.21

0.35

0.15

Ferritin (ng/ml)

—

120.4

—

—

420.3

—

—

339.7

—

361.8

324.0

219.3

193.8

215.6

238.2

178.7

173.8

TSAT (%)

27.5

24.0

21.8

30.2

30.4

45.5

32.3

44.5

50.9

56.2

82.4

41.8

57.1

39.3

40.8

26.8

28.3

BMI (kg/m2)

22.1

22.0

21.9

21.9

22.1

22.1

22.2

22.4

22.4

22.4

22.2

21.9

21.9

21.8

21.6

21.8

21.5

Pulse rate (ppm)

64.1

69.6

65.5

67.4

69.5

65.4

68.5

67.1

67.4

71.8

71.7

73.4

69.9

68.6

67.5

65.6

63.8

SBP (mmHg)

146.3

153.3

149.6

139.7

140.4

138.7

147.2

141.2

144.5

150.3

162.7

160.0

153.8

151.4

154.0

151.2

148.0

DBP (mmHg)

70.0

76.2

72.3

68.5

69.5

69.3

71.2

66.6

69.0

74.4

78.4

73.1

70.2

71.4

71.6

71.5

68.2

  1. Treatment for renal anemia was switched from darbepoetin alfa to roxadustat. The treatment with roxadustat was done from February 2 to June 12, 2020. Measurements were done in the last week of each month. Note the reductions of TC, Non-HDL-C, and HDL-C levels during roxadustat treatment.
  2. Abbreviations: DARBE darbepoetin alfa; ROXAD roxadustat; TC total cholesterol; Non-HDL-C non-high-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; AST aspartate aminotransferase; ALTalanine aminotransferase; BUN blood urea nitrogen; CRP C-reactive protein; TSAT transferrin saturation; BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure